Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Open Access
- 27 October 2014
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (45) , E4869-E4877
Abstract
Significance: Inhibitors of the FGF receptors (FGFRs) are currently under clinical investigation for the treatment of various cancers. All currently approved kinase inhibitors eventually are rendered useless by the emergence of drug-resistant tumors. We used structure-based drug design to develop the first, to our knowledge, selective, next-generation covalent FGFR inhibitors that can overcome the most common form of kinase inhibitor resistance, the mutation of the so-called “gatekeeper” residue located in the ATP-binding pocket. We also describe a novel kinase inhibitor design strategy that uses a single electrophile to target covalently cysteines that are located in different positions within the ATP-binding pocket. These results have important implications for the design of covalent FGFR inhibitors that can overcome clinical resistance.Keywords
This publication has 98 references indexed in Scilit:
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersApoptosis, 2013
- FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal CancerPLOS ONE, 2013
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesBlood Cancer Journal, 2012
- High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase InhibitorsChemistry & Biology, 2011
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent InhibitorsJournal of Medicinal Chemistry, 2011
- A Structure-Guided Approach to Creating Covalent FGFR InhibitorsChemistry & Biology, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancerDrug Resistance Updates, 2009
- A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine KinasesMolecular Cell, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007